GSK plc reports

Company location
London
GSK plc has filed 6,818 SEC EDGAR filings since 12 Jan 2001

SEC filing history

Showing 851-875 of 1,000 matching filings.

Per page
25
Current page
35
6-K File 001-15170

STATEMENT: ZANTAC (RANITIDINE) LITIGATION

Filing date
24 Mar 2023
Reporting date
24 Mar 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
21 Mar 2023
Reporting date
21 Mar 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
20 Mar 2023
Reporting date
20 Mar 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
EFFECT File 333-254756

EFFECT filing

Filing date
15 Mar 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

POSITIVE PHASE III RESULTS FOR MENABCWY VACCINE

Filing date
14 Mar 2023
Reporting date
14 Mar 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

NUCALA NDA ACCEPTED FOR REVIEW IN CHINA

Filing date
14 Mar 2023
Reporting date
14 Mar 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
13 Mar 2023
Reporting date
13 Mar 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
POS AM File 333-254756

POS AM

Filing date
10 Mar 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

GSK ANNUAL REPORT 2022 ON FORM 20-F

Filing date
10 Mar 2023
Reporting date
10 Mar 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
IRANNOTICE File 001-15170

IRANNOTICE

Filing date
10 Mar 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

GSK PUBLISHES ANNUAL REPORT 2022

Filing date
10 Mar 2023
Reporting date
10 Mar 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

FDA AD COM VOTES TO SUPPORT GSK RSV OA VACCINE

Filing date
02 Mar 2023
Reporting date
02 Mar 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TOTAL VOTING RIGHTS

Filing date
01 Mar 2023
Reporting date
01 Mar 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
27 Feb 2023
Reporting date
27 Feb 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
23 Feb 2023
Reporting date
23 Feb 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

VIIV HEALTHCARE ANNOUNCES CABENUVA POSITIVE DATA

Filing date
23 Feb 2023
Reporting date
23 Feb 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
22 Feb 2023
Reporting date
22 Feb 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

NEJM PUBLISHES GSK RSV OA VACCINE CANDIDATE TRIAL

Filing date
16 Feb 2023
Reporting date
16 Feb 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
15 Feb 2023
Reporting date
15 Feb 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
15 Feb 2023
Reporting date
15 Feb 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-84251

SC 13G/A

Filing date
14 Feb 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
14 Feb 2023
Reporting date
14 Feb 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
14 Feb 2023
Reporting date
14 Feb 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
14 Feb 2023
Reporting date
14 Feb 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .